MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population

Cancer Epidemiology

Volumn 34, Issue 4, 2010, Pages 448-452

  Akkiz, Hikmet ^a   Sümbül, Ahmet Taner ^b   Bayram, Süleyman ^a   Bekar, Aynur ^a   Akgöllü, Ersin ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Hepatocellular carcinoma; MDM2 SNP309 T G polymorphism; PCR RFLP; Single nucleotide polymorphism; Susceptibility

Indexed keywords

PROTEIN MDM2; DNA; MDM2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC); BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; TURKEY;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SURVIVAL RATE; TURKEY;

EID: 77955680497     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.04.008     Document Type: Article

References (46)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
3. McKillop I.H., Moran D.M., Jin X., Koniaris L.G. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006, 136:125-135.
4. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
5. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
6. Kirk G.D., Turner P.C., Gong Y., Lesi O.A., Mendy M., Goedert J.J., et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev 2005, 14:373-379.
7. Jung Y.J., Kim Y.J., Kim L.H., Lee S.O., Park B.L., Shin H.D., et al. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology 2007, 50:369-376.
8. Mayo L.D., Donner D.B. The PTEN Mdm2, p53 tumor suppressoroncoprotein network. Trends Biochem Sci 2002, 27:462-467.
9. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
10. Freedman D.A., Wu L., Levine A.J. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999, 55:96-107.
11. Moll U.M., Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003, 1:1001-1008.
12. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
13. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
14. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
15. Martin K., Trouche D., Hagemeier C., Sorensen T.S., La Thangue N.B., Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995, 375:691-694.
16. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698.
17. Brown D.R., Thomas C.A., Deb S.P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998, 17:2513-2525.
18. Momand J., Zambetti G.P. Mdm-2: 'big brother' of p53. J Cell Biochem 1997, 64:343-352.
19. National Institute of Environmental Health Sciences. Environmental Genome Projects. 2004; NIEHS SNPS.
20. Bond G.L., Hu W., Bond E.E. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
21. Zhang X., Miao X., Guo Y., Tan W., Zhou Y., Sun T., et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006, 27:110-117.
22. Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T., et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006, 12:4867-5487.
23. Ezzikouri S., El Feydi A.E., Afifi R., El Kihal L., Benazzouz M., Hassar M., et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 2009, 32:380-385.
24. Yoon Y.J., Chang H.Y., Ahn S.H., Kim J.K., Park Y.K., Kang D.R., et al. MDM2 and p53 Polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008, 29:1192-1196.
25. Leu J.-D., Lin F.-I., Sun Y.-F., Chen S.-M., Liu C.-C., Lee Y.-J. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 2009, 15:5592-5597.
26. Ohmiya N., Taguchi A., Mabuchi N., Itoh A., Hirooka Y., Niwa Y., et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006, 24:4434-4440.
27. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of non-small cell lung cancer. Int J Cancer 2006, 119:718-721.
28. Walsh C.S., Miller C.W., Karlan B.Y., Koeffler H.P. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007, 104:660-664.
29. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005, 65:9582-9587.
30. Onat O.E., Tez M., Ozcelik T., Toruner G.A. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 2006, 26:3473-3475.
31. Ma H., Hu Z., Zhai X., Wang S., Wang X., Qin J., et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006, 240:261-267.
32. Campbell I.G., Eccles D.M., Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006, 240:195-197.
33. Alhopuro P., Ylisaukko-Oja S.K., Koskinen W.J., Bono P., Arola J., Jarvinen H.J., et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005, 42:694-698.
34. Tsai J.F., Chang W.Y., Jeng J.E., Ho M.S., Lin Z.Y., Tsai J.H. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994, 14:98-102.
35. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Peitroni M.C., Williams R. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973, 60:646-649.
36. Sambrook J., Frits E.F., Mnniatis T. Molecular Cloning: A Laboratory Mannual 1989, Cold Spring Harbor, New York. second ed.
37. Sotamaa K., Liyanarachchi S., Mecklin J.P., Järvinen H., Aaltonen L.A., Peltomäki P., et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005, 11:6840-6844.
38. Bond G.L., Hu W., Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005, 65:5481-5484.
39. Bond G.L., Levine A.J. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007, 26:1317-1323.
40. Dobbelstein M., Wienzek S., Konig C., Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 1999, 18:2101-2106.
41. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734.
42. Soussi T., Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1:233-240.
43. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a TP53-associated protein in human sarcomas. Nature 1992, 358:80-83.
44. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., Bradley A. Overexpression of Mdm2 in mice reveals a TP53- independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998, 95:15608-15612.
45. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G. The sequence of the human genome. Science 2001, 291:1304-1351.
46. Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.